Comparison · NCT02993783-sae
Vedolizumab 300 mg vs Vedolizumab 600 mg: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vedolizumab 300 mg vs Vedolizumab 600 mg: serious adverse events. Trial comparisons, record NCT02993783-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02993783-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.75 | 0.409 | 0.929 | wilson | |
| Risk in group 2 | 1 | 0.701 | 1 | wilson | |
| Risk difference, group 1 minus group 2 | -0.25 | -0.591 | 0.0984 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.75 | 0.503 | 1.12 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with a serious adverse event on Vedolizumab 300 mg than on Vedolizumab 600 mg | 4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vedolizumab 300 mg | Vedolizumab 300 mg, IV infusion, once on Days 1, 15, 43, 71 and 99. | 6 | 8 | EG000 |
| Group 2 | Vedolizumab 600 mg | Vedolizumab 600 mg, IV infusion, once on Days 1, 15, 43, 71 and 99. | 9 | 9 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From first dose of study drug to 18 weeks after the last dose of study drug (Up to approximately 32 weeks)
Source ClinicalTrials.gov
Trial
- Title
A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
- NCT number
- NCT02993783
- Phases
- PHASE2
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- Interventions
- Vedolizumab
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Results first posted
- 2019-05-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02993783?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02993783-sae